SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Chip

CHIP is trending as market participants debate its utility as an AI infrastructure and GPU-backed lending play versus concerns over its volatile price action and tokenomics. While some investors highlight its real-world financing of AI hardware as a long-term catalyst, others express skepticism, frequently describing the token as a high-risk asset prone to aggressive short-selling and speculative trading patterns.

Block, Inc. engages in creating ecosystems for distinct customer audiences. It operates through the following segments: Square and Cash App. The Square segment provides payment services, software solutions, hardware, and financial services to sellers. The Cash App segment includes the financial tools available to individuals within the mobile Cash App, including peer-to-peer payments, bitcoin and stock investments. The company was founded by Jack Patrick Dorsey and James Morgan McKelvey in February 2009 and is headquartered in Oakland, CA.

Block Inc - Ordinary Shares - Class A

Block Inc

Block is drawing attention as the market evaluates its fintech pivot, with investors closely watching the company's progress on streamlining operations and its long-term growth potential. While some community members remain skeptical of the stock's range-bound performance, others are monitoring institutional activity and technical levels for signs of a potential breakout.

Flowers Foods, Inc. engages in the production and marketing of packaged bakery foods. It offers breads, buns, rolls, snack items, bagels, English muffins, and tortillas and are sold under a variety of brand names, including Nature’s Own, Dave’s Killer Bread, Wonder, Canyon Bakehouse, Tastykake, and Mrs. Freshley’s. The company was founded by William Howard Flowers, Sr. and Joseph Hampton Flowers, Jr. in 1919 and is headquartered in Thomasville, GA.

Flowers Foods, Inc.

Flowers Foods is trending due to significant investor speculation regarding a potential buyout and concerns over heavy short interest, which remains high despite recent price volatility. Community members are actively debating the company's long-term value, the safety of its dividend, and whether the stock's recent price action signals an impending short squeeze leading into upcoming earnings.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JasmyCoin is currently facing intense debate as investors weigh the project's long-term IoT utility against aggressive community criticism labeling it an abandoned scam. Market participants are actively split between those aggressively dollar-cost averaging in anticipation of future ecosystem developments and others shorting the asset as they rotate capital into newer projects.

Chainlink is the industry-standard decentralized oracle network that solves the "oracle problem" by connecting smart contracts with real-world data. Blockchains cannot access external information on their own, so Chainlink acts as a secure bridge, enabling smart contracts to react to real-world events using verified, tamper-proof data. It is widely considered one of the first decentralized oracle networks and is the market leader in bringing off-chain data on-chain.  The platform operates through a decentralized network of nodes that fetch, validate, and deliver data to smart contracts. When a contract requests information like a stock price, a committee of independent nodes retrieves and aggregates the data to reach consensus, then delivers a single trustworthy answer. Chainlink offers a suite of services including Data Feeds for asset prices, CCIP for cross-chain token transfers and messaging, Automation for triggering smart contract functions, and Proof of Reserve for verifying asset collateralization.  Chainlink has established itself as critical infrastructure for both DeFi and institutional adoption, with partnerships including Swift, Euroclear, Mastercard, UBS, ANZ, Fidelity International, and J.P. Morgan. Its institutional products include the Chainlink Runtime Environment for tokenized asset workflows, Confidential Compute for privacy-preserving computation, and the Automated Compliance Engine for embedding regulatory rules into smart contracts.  The LINK token is the native asset used to pay node operators for services, fund subscription accounts, and incentivize network security through staking. Node operators stake LINK as collateral, which can be slashed if they provide inaccurate data. Chainlink was co-founded in 2017 by Sergey Nazarov and Steve Ellis, who co-authored the white paper with Ari Juels, and raised $32 million in its September 2017 ICO.

ChainLink

Chainlink is seeing active discussion as the community debates its long-term potential as critical oracle infrastructure versus its recent price underperformance and tokenomics. Sentiment is split between those accumulating in anticipation of broader RWA and institutional adoption and those frustrated by the coin's historical price volatility and lack of correlation with major market moves.

Avalanche is a high throughput smart contract blockchain&nbsp;platform. Validators secure the network through a proof-of-stake consensus protocol. It is said to be fast, low cost, and environmental friendly.

Avalanche

Avalanche is currently facing intense selling pressure and negative sentiment as investors grapple with its steep year-to-date decline and persistent failure to decouple from broader market weaknesses. While some community members remain focused on long-term accumulation and the network's ongoing real-world adoption, others are actively debating whether the token has become a value trap in a crowded and competitive L1 sector.

WeRide, Inc. operates as an investment holding company. It engages in the sale of autonomous driving vehicles, primarily including robobuses, robotaxis, robosweepers and related sensor suites. The company was founded by Tony Xu Han and Yan Li in February 2017 and is headquartered in Guangzhou, China.

WeRide Inc. - ADR

WeRide is currently trending as investors scrutinize its operational performance ahead of Q1 earnings, with the community closely tracking the company's aggressive global fleet expansion and the potential impact of its proprietary autonomous driving solutions. Market sentiment is heavily focused on the company's ability to convert its high-profile partnerships, such as those with Uber and Geely, into tangible revenue growth and improved unit economics.

Almonty Industries, Inc. engages in the mining, processing, and shipment of tungsten concentrates. Its projects include Almonty Korea Tungsten, Panasquiera mine, Gentung, Almonty Korea Moly, Los Santos mine, and Valtreixal. The company was founded on September 28, 2009 and is headquartered in Dillon, MT.

Almonty Industries Inc

Almonty Industries is trending as investors monitor the company's ramp-up of its Sangdong mine in South Korea and its strategic role as a primary non-Chinese supplier of tungsten, a critical material for the defense and semiconductor sectors. The community is actively discussing institutional accumulation, the impact of rising global tungsten prices, and the company's anticipated alignment with U.S. defense supply chain mandates.

Symbotic, Inc. is an automation technology company, which engages in a robotics and automation-based product movement technology platform. It focuses on developing, commercializing, and deploying innovative, end-to-end technology solutions for supply chain operations. It operates through the United States and Canada geographical segments. The company was founded by Richard B. Cohen on December 11, 2020 and is headquartered in Wilmington, MA.

Symbotic Inc - Ordinary Shares - Class A

Symbotic Inc 

Symbotic is seeing heightened investor attention following a mixed earnings report that highlighted strong revenue growth and a return to profitability, though some investors are closely monitoring execution pace and backlog stagnation. The community remains divided, with bulls pointing to the company's long-term potential in AI-driven warehouse automation and a multi-billion dollar backlog, while bears express concern over high valuation multiples, customer concentration risks, and the speed of system deployments.

Agenus, Inc. is a clinical-stage company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes Balstilimab, Zalifrelimab, AGEN1181, AGEN1327, AGEN2373, AGENt-797 and AGEN1777. The company was founded by Garo H. Armen and Pramod K. Srivastava on March 31, 1994 and is headquartered in Lexington, MA.

Agenus Inc

Agenus is trending following an oversubscribed private placement of up to $340 million, which has secured the necessary funding to advance its pivotal Phase 3 ROBBIN trial for a neoadjuvant colon cancer treatment. The community is actively discussing the stock's significant institutional backing, the strategic pivot to a high-value addressable market, and the implications of the warrant-based financing structure on potential share dilution.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Alterity Therapeutics Secures Key US Patent for Lead Asset

Alterity Therapeutics secured a USPTO patent for ATH434, extending market protection for its neurodegenerative drug candidate to 2045.read more...

Is Allarity Therapeutics, Inc. (ALLR) Outperforming Other Medical Stocks This Year?

Here is how Allarity Therapeutics, Inc. (ALLR) and Alterity Therapeutics Limited - Sponsored ADR (ATHE) have performed compared to their sector so far this year.

Alterity Therapeutics Advances Lead Drug Towards Pivotal Study For Rare Neuromuscular Disorder

Alterity Therapeutics advances ATH434 toward Phase 3 after FDA alignment on trial design for MSA, while shares decline in premarket trading.read more...

Alterity Therapeutics Gets Positive FDA Feedback On ATH434 Phase 3 Study

(RTTNews) - Alterity Therapeutics Limited (ATHE) on Monday said it received positive feedback from the U.S. Food and Drug Administration following a Type C meeting regarding its planned Phase 3 program for ATH434 in Multiple System Atrophy (MSA...

Alterity Therapeutics Gains FDA Backing For Phase 3 MSA Trial

(RTTNews) - Alterity Therapeutics (ATHE, ATH.AX) announced that it has received positive regulatory feedback following a Type C Meeting with the U.S. Food and Drug Administration (FDA) regarding its planned Phase 3 development program for ATH434 in Multiple System Atrophy (MSA...

Alterity Therapeutics Announces Appointment Of Daniel Claassen As Chief Medical Advisor

(RTTNews) - Alterity Therapeutics Limited (ATHE), Wednesday announced the appointment of Daniel Claassen as Chief Medical Advisor, effective March 2026...

Alterity Therapeutics Stock Doubles Premarket On Positive MSA Trial Results: Retail Excitement Soars

Equity

A 50mg dose of its ATH434 showed 8% reduction in clinical progression of early-stage multiple system atrophy vs. placebo.  

Alterity Therapeutics Ltd. is a clinical stage biotechnology company. It engages in the business of research and development of therapeutic drugs designed to treat the underlying cause of degeneration of the brain focusing on Alzheimer's, Huntington, Parkinson’s, and other neurological disorders. The company was founded by Geoffrey Paul Kempler on November 11, 1997 and is headquartered in Melbourne, Australia.

Alterity Therapeutics Ltd - ADR

Bullish Sentiment

Up more than 1% 

Flat to up 1%

Flat to down 1%

Down more than 1%

The S&P 500 ($SPY) is headed towards a winning week. What do you think the index's return will look like next week? Vote and explain your reasoning in the comments.

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Feed

News

Sentiment

Fundamentals

Info

ATHEAlterity Therapeutics Ltd - ADR

Fundamentals

Connect Stocktwits to ChatGPT

Latest ATHE News